{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:06Z","timestamp":1792218606215,"version":"4.4.0"},"reference-count":37,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,7,14]]},"abstract":"<jats:p> PURPOSE: To determine the efficacy and toxicity of docetaxel in patients with m\u00fcllerian carcinoma resistant to paclitaxel. <\/jats:p><jats:p> PATIENTS AND METHODS: Thirty-two patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who failed paclitaxel-based chemotherapy received either 100 or 75 mg\/m<jats:sup>2<\/jats:sup> of docetaxel every 3 weeks. Resistance to paclitaxel was defined as either progression of disease during treatment, failure to achieve regression of disease after at least four courses, or rapid recurrence (within 6 months) after completion of therapy. <\/jats:p><jats:p> RESULTS: Eighteen patients were treated on a formal protocol and fourteen with the commercially available docetaxel. Thirty were assessable for response. Toxicities were thoroughly evaluated in the 18 patients on protocol. Twenty-seven patients (85%) had epithelial ovarian cancer. The overall response rate was 23% (one complete and six partial responses), with a median survival time of 44 weeks (9.5 months). Nine patients had stable disease and 14 progressive disease. Among 19 patients who progressed during prior paclitaxel treatment, two (11%) responded to docetaxel, compared with five (45%) of 11 patients in other paclitaxel-resistance categories. The responders had a median taxane-free interval (ie, the time between the last paclitaxel and first docetaxel treatment) of 73 weeks, compared with 19 weeks for the nonresponder group. Toxic effects were as expected. <\/jats:p><jats:p> CONCLUSION: Docetaxel is an active chemotherapeutic agent in patients with m\u00fcllerian carcinoma previously treated with paclitaxel-based chemotherapy, especially in the patients who had a long taxane-free interval after a previous short response to paclitaxel. <\/jats:p>","DOI":"10.1200\/jco.2000.18.14.2733","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:50:00Z","timestamp":1487919000000},"page":"2733-2739","source":"Crossref","is-referenced-by-count":114,"title":["Docetaxel for Patients With Paclitaxel-Resistant M\u00fcllerian Carcinoma"],"prefix":"10.1200","volume":"18","author":[{"given":"Claire F.","family":"Verschraegen","sequence":"first","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tul","family":"Sittisomwong","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej P.","family":"Kudelka","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto de Paula","family":"Guedes","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Steger","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarra","family":"Nelson-Taylor","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Vincent","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Rogers","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Neely","family":"Atkinson","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine Specialties and BiomathematicsUniversity of Texas M.D. Anderson Cancer Center, Houston; M.D. Anderson Outreach, Clear Lake, TX; Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand; and Department of Gynecologic Oncology, Irmandade Santa Casa Misericordia de Porto Alegre Hospital, Porto Alegre, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0359","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.50.1.7"},{"key":"R2-0359","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101"},{"key":"R3-0359","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050177"},{"key":"R4-0359","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008240421028"},{"key":"R5-0359","unstructured":"McGuire  WP,  Ozols  RF:  Chemotherapy of advanced ovarian cancer.  Semin Oncol 25:340,1998-348,"},{"key":"R6-0359","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.1999.09856.x"},{"key":"R7-0359","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90011-2"},{"key":"R8-0359","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.4.288"},{"key":"R9-0359","doi-asserted-by":"publisher","DOI":"10.1021\/bi00062a003"},{"key":"R10-0359","doi-asserted-by":"publisher","DOI":"10.1007\/BF01886864"},{"key":"R11-0359","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199204000-00008"},{"key":"R12-0359","doi-asserted-by":"crossref","unstructured":"Untch  M,  Untch  A,  Sevin  BU, et al:  Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.  Anticancer Drugs 5:24,1994-30,","DOI":"10.1097\/00001813-199402000-00004"},{"key":"R13-0359","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3362"},{"key":"R14-0359","unstructured":"Aapro  M,  Pujade-Lauraine  E,  Lhomme  C, et al:  Phase II study of Taxotere (T) in ovarian cancer. EORTC Clinical Screening Group (CSG).  Proc Am Soc Clin Oncol 12:256a,1993  (abstr 809)"},{"key":"R15-0359","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2301"},{"key":"R16-0359","unstructured":"Kavanagh  JJ,  Kudelka  AP,  Gonzalez de Leon  C, et al:  Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.  Clin Cancer Res 2:837,1996-842,"},{"key":"R17-0359","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.9.676"},{"key":"R18-0359","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2471"},{"key":"R19-0359","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R22-0359","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.699"},{"key":"R23-0359","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008323922057"},{"key":"R24-0359","unstructured":"Sabbatini  P,  Spriggs  D:  Salvage therapy for ovarian cancer.  Oncology (Huntingt) 12:833,1998-843,"},{"key":"R25-0359","unstructured":"Alberts  DS:  Treatment of refractory and recurrent ovarian cancer.  Semin Oncol 26:8,1999-14,"},{"key":"R26-0359","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2643"},{"key":"R27-0359","unstructured":"Tresukosol  D,  Kudelka  AP,  Gonzales de Leon  C, et al:  Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer.  Eur J Gynaecol Oncol 17:188,1996-191,"},{"key":"R28-0359","unstructured":"Riva  A,  Fumoleau  P,  Roche  H:  Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (pts) treated with Taxotere (T).  Proc Am Soc Clin Oncol 16:188a,1997  (abstr 660)"},{"key":"R29-0359","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2183"},{"key":"R30-0359","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1552"},{"key":"R31-0359","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.987"},{"key":"R32-0359","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90580-0"},{"key":"R33-0359","unstructured":"Horwitz  SB,  Cohen  D,  Rao  S, et al:  Taxol:  Mechanisms of action and resistance. J Natl Cancer Inst Monogr 15:55,1993-61,"},{"key":"R34-0359","unstructured":"Haldar  S,  Basu  A,  Croce  CM:  2 is the guardian of microtubule integrity.  Cancer Res 57:229,1997-233,  Bcl"},{"key":"R35-0359","doi-asserted-by":"crossref","unstructured":"Minotti  AM,  Barlow  SB,  Cabral  F:  Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin.  J Biol Chem 266:3987,1991-3994,","DOI":"10.1016\/S0021-9258(19)67891-9"},{"key":"R36-0359","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199911001-00006"},{"key":"R37-0359","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199807000-00009"},{"key":"R38-0359","unstructured":"Khayat  D,  Antoine  E:  Docetaxel in combination chemotherapy for metastatic breast cancer.  Semin Oncol 24:S13-19,1997-S13-26,   (suppl 13)"},{"key":"R39-0359","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2069"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.14.2733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:37:10Z","timestamp":1653514630000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.14.2733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7,14]]},"references-count":37,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2000,7,14]]}},"alternative-id":["10.1200\/JCO.2000.18.14.2733"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.14.2733","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7,14]]}}}